Cargando…

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor

Bispecific T-cell engager antibodies (BiTE) have been explored as a means to recruit cytolytic T cells to kill tumor cells. The transferrin receptor (TfR) is highly expressed on the surface of rapidly proliferating tumor cells. Therefore, it holds great potential in T cell redirecting therapies. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Mingpeng, He, Qi, Guo, Zilong, Zhou, Xiaoran, Li, Heli, Zhao, Liang, Tang, Hongling, Zhou, Xiaoqi, Zhu, Huifen, Shen, Guanxin, He, Yong, Lei, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598450/ https://www.ncbi.nlm.nih.gov/pubmed/31293575 http://dx.doi.org/10.3389/fimmu.2019.01396

Ejemplares similares

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

Establishment of a hTfR mAb-functionalized HPPS theranostic nanoplatform
por: He, Qi, et al.
Publicado: (2020)

GRP78 Impairs Production of Lipopolysaccharide-Induced Cytokines by Interaction with CD14
por: Qin, Kai, et al.
Publicado: (2017)

Secreted glucose regulated protein78 ameliorates DSS-induced mouse colitis
por: Zhao, Liang, et al.
Publicado: (2023)

Endocytosis of a Functionally Enhanced GFP-Tagged Transferrin Receptor in CHO Cells
por: He, Qi, et al.
Publicado: (2015)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Bispecific Antibodies: From Research to Clinical Application
por: Ma, Jiabing, et al.
Publicado: (2021)

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
por: Liu, Hongyan, et al.
Publicado: (2017)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Glucose-Regulated Protein 78-Induced Myeloid Antigen-Presenting Cells Maintained Tolerogenic Signature upon LPS Stimulation
por: Yang, Muyang, et al.
Publicado: (2016)

Tumor-Secreted GRP78 Promotes the Establishment of a Pre-metastatic Niche in the Liver Microenvironment
por: Chen, Lu, et al.
Publicado: (2020)

IL-23 enhances the malignant properties of hepatoma cells by attenuation of HNF4α
por: Jiang, Qing, et al.
Publicado: (2018)

Immunotherapeutic progress and application of bispecific antibody in cancer
por: Kang, Jingyue, et al.
Publicado: (2022)

Prospective Design of Anti‐Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain
por: Kanodia, JS, et al.
Publicado: (2016)

VHH-Based Bispecific Antibodies Targeting Cytokine Production
por: Nosenko, Maxim A., et al.
Publicado: (2017)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
por: Lejeune, Margaux, et al.
Publicado: (2020)

Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1
por: Qi, Junpeng, et al.
Publicado: (2019)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
por: van Diest, Eline, et al.
Publicado: (2023)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021)

Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
por: Kubicka, Ewa, et al.
Publicado: (2022)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022)

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition
por: Yeku, Oladapo O., et al.
Publicado: (2021)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
por: Shi, Ning, et al.
Publicado: (2022)

Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
por: Shin, Ha Gyeong, et al.
Publicado: (2022)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
por: Xiao, Xinghui, et al.
Publicado: (2023)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling
por: Jackman, Janet, et al.
Publicado: (2010)

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
por: Loh, Han Ping, et al.
Publicado: (2023)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
por: Satta, Alessandro, et al.
Publicado: (2019)

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
por: Rabia, Emilia, et al.
Publicado: (2023)

Generation of bispecific antibodies by structure-guided redesign of IgG constant regions
por: Iwasaki, Yordkhwan W., et al.
Publicado: (2023)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
por: Candelaria, Pierre V., et al.
Publicado: (2021)

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
por: Del Bano, Joanie, et al.
Publicado: (2019)

Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies
por: Blanco, Belén, et al.
Publicado: (2020)

CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses
por: Molony, Ryan D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1n1m6n3878gmme4hl938kamp01